Compare Atomera Incorporated (ATOM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Novo Nordisk A/S — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while Novo Nordisk A/S trades at $47.23 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 989.3× Atomera Incorporated's market cap, and Novo Nordisk A/S pays a 3.76% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ATOM | NVO | |
|---|---|---|
Market Cap | $209.56M | $207.31B |
Sector | Technology | Health |
52-Week High | $12.11 | $63.98 |
52-Week Low | $1.99 | $35.29 |
Enterprise Value | $172.37M | $222.02B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
